Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012OC055 Principal Investigator Smith, Angela
Phase NA
Age Group Both Scope Local
Title MT2012-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Objective Endpoints include time to engraftment, incidence of graft failure, incidence of chimerism at 100 days, 6 months, and 1 year; incidence of acute graft-versus-host disease (GVHD) at 100 days and chronic GVHD at 6 months and 1 year; incidence of transplant related mortality at 6 months and incidence of disease free survival and overall survival at 6 months.
Treatment Based on diagnosis and clinically history, a determination of the most appropriate regimen will be made based on the following prep plans: Arm A: Fully Myeloablative Preparative Regimen Arm B: Reduced Toxicity Ablative Preparative Regimen Arm C: Reduced Intensity Conditioning Arm D: No Preparative Regimen
Description This is a treatment guideline for allogeneic hemapoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Key Eligibility Diagnosis of immunodeficiency or histiocytic disorder.
Applicable Disease Sites Bone Marrow
Other Hematopoietic
Therapies Involved Blood and Marrow Transplant
Drugs Involved Alemtuzumab (Campath)
BUSULFAN (MYLERAN)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
FLUDARABINE (FLUDARA)
Status Open
Participating Institutions Masonic Cancer Center
Detailed Eligibility Must be no more than 50 years of age and have an identified stem cell source. Adequate organ function is required. Women who are pregnant or nursing are not eligible. Anyone with an active uncontrolled infection, HIV positive, or acute hepatitis is not eligible. A signed informed consent and HIPAA authorization are required.
Treatment Type Non-Cancer Therapeutic
Contact Cancer Information Line nurse Phone: 612-624-2620 - 1-888-226-2376
Email: ccinfo@umn.edu